Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 5Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Recurrence 1Plasmacytoma 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Myeloid Malignancies 1Myelodysplastic Syndromes 1Multiple Myeloma 1Microsatellite Stable Colorectal Carcinoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Hematologic Neoplasms 1Hematologic Diseases 1Head and Neck Neoplasms 1Epstein-Barr Virus Infections 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Cyclophosphamide 41fludarabine 35Tacrolimus 28Mycophenolic Acid 27Whole-Body Irradiation 25Busulfan 24fludarabine phosphate 21Melphalan 19thymoglobulin 16Antilymphocyte Serum 16Methotrexate 13Thiotepa 12Stem Cell Transplantation 9Rituximab 9Granulocyte Colony-Stimulating Factor 9Filgrastim 8Cyclosporine 8trametinib 7Sirolimus 7Nivolumab 5ruxolitinib 4merphos 4Peripheral Blood Stem Cell Transplantation 4Cytarabine 4Cord Blood Stem Cell Transplantation 4Bendamustine Hydrochloride 4tocilizumab 3itacitinib 3fedratinib 3dabrafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hematologic Neoplasms × cc-486 × Clear all
NCT02494258 2026-04-02

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Celgene

Phase 2 Completed
5 enrolled 10 charts
Other hematologic neoplasm

Hematologic Diseases, Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡